about
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersPARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignanciesFunctional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi originLarge-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repairClinical and molecular characterization of the BRCA2 p.Asn3124Ile variant reveals substantial evidence for pathogenic significance.Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experienceNovel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals.A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancerThe CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers.Whole exome sequencing reveals concomitant mutations of multiple FA genes in individual Fanconi anemia patients.Genetic tests: clinical validity and clinical utilityMutations in BRCA2 and taxane resistance in prostate cancerBRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data.Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner.The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriersPotentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation.Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous studyReligiosity, spirituality, and psychological distress in African-Americans at risk for having a hereditary cancer predisposing gene mutation.Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Triple-negative breast cancer: new perspectives for targeted therapies.An update on PARP inhibitors for the treatment of cancerCancer worry among Norwegian male BRCA1/2 mutation carriers.Effects of Radiation Therapy on Breast Epithelial Cells in BRCA1/2 Mutation CarriersCharacterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase.40 years of progress in female cancer death risk: a Bayesian spatio-temporal mapping analysis in SwitzerlandAge of 40 years or younger is an independent risk factor for locoregional failure in early breast cancer: a single-institutional analysis in saudi arabia.Constitutive expression of AhR and BRCA-1 promoter CpG hypermethylation as biomarkers of ERα-negative breast tumorigenesisBRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.Diagnosis of Fanconi Anemia: Mutation Analysis by Multiplex Ligation-Dependent Probe Amplification and PCR-Based Sanger SequencingTreatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: a case report.MUTYH gene variants and breast cancer in a Dutch case–control study.The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from UkraineNovel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations.BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease Pathogenesis.Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphismMammographic density, breast cancer risk and risk prediction.gDNA enrichment by a transposase-based technology for NGS analysis of the whole sequence of BRCA1, BRCA2, and 9 genes involved in DNA damage repair.Genetic evaluation of BRCA1 associated a complex genes with triple-negative breast cancer susceptibility in Chinese women.
P2860
Q27006938-44F4F7DD-2DBA-4211-B99E-D2A7FF045303Q27027503-5CFE27D8-2F82-4643-922F-A6961EA2AEBEQ28260374-E9CC15F1-8978-4797-A99C-379FD73B6457Q28267893-4BBC9FE5-1891-4B41-AC0F-2CFDFD3C3BD2Q30361333-13A92637-2311-49A5-A4A8-0776A9508D28Q33308326-1BEEDB94-21D8-4B87-AFE3-A8D569ADA1ABQ33355677-BE23C90F-5395-4FE0-8DFD-FEE63D7956A7Q33584346-B6AB5FAD-A888-420B-963F-A2404E5E6275Q33675997-6C931E13-EB1F-4567-96D7-A1B81A93E6DEQ33686055-4BFE7625-EA1D-4230-A186-C6EB80FA2435Q33856320-1FB0E20F-EDAF-4CCE-853A-53169F4E4249Q33870601-30A16ED5-6A34-4690-BE03-1F2F6E49CB91Q33881971-05F38E5F-088D-468B-A9D5-BEB4B3A5737FQ34109373-7F00FFB9-D8DA-4BEF-81A2-64E2FBDDC012Q34115636-FF48795D-BC8D-4B5C-9FDE-470BA313A8C4Q34146866-F03C145D-4DE3-48B6-B76E-A1624AC15BB4Q34311315-C6482CF2-90B2-4C04-B1F4-F777583D6E2EQ34582236-2138F7A1-146F-4443-B411-28844F2D7899Q34963894-995A5407-4640-42B4-BDBD-D1CE260FDFE1Q35001758-DF280907-1AD6-4BF7-A7BD-F1A8103BA819Q35142718-FF3BA082-7733-4E7E-9FDC-33482F2270F7Q35219186-4308340A-62FC-4612-A6A9-5544C31D3A0CQ35679122-7D274DEF-4C55-4AB1-9CFD-FE6BEE657058Q35801868-37901CA0-544F-43E9-9908-B2AD3A535EB5Q35802313-FE6B5D4B-7D05-42B9-9DCA-DC925A17C8CEQ35876120-5AF68F6E-F66F-4F6C-9FC7-CC1882D6F938Q35881326-DD1BC914-0117-46B0-83B4-86B1F255CA73Q36064826-1C729883-8970-46F9-9667-76B0B3873316Q36072260-87CB8EAF-3D52-4ED6-B96E-0CAB30A9A825Q36094171-1AD89D79-FC88-4831-8AEE-2172D0834983Q36095933-32311BED-0AC1-4CD0-90FE-0D315A2EF663Q36161162-86944351-535D-4CE2-8E80-601FF6CE3B97Q36230861-CD479360-957B-41BD-8C19-F2BBA2B7E9AAQ36347042-C500EEA4-0805-4487-B251-2E23384391D4Q36365669-87D80E51-D9F6-405A-A141-4EB95C2E792DQ36398266-E2679413-CE5A-4FE8-B0F8-FDC25F784408Q36458780-F2C02862-6978-4E5F-9BFA-1232A41C9FA7Q36465317-3820C621-379D-4FFE-A74A-60F5E7B7D314Q36788376-BA918C53-EA5C-4EA0-AE4F-8583FB403F24Q36962780-85F18D8B-02A5-4671-BF90-DC478DC88C6F
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cancer risks among BRCA1 and BRCA2 mutation carriers.
@ast
Cancer risks among BRCA1 and BRCA2 mutation carriers.
@en
type
label
Cancer risks among BRCA1 and BRCA2 mutation carriers.
@ast
Cancer risks among BRCA1 and BRCA2 mutation carriers.
@en
prefLabel
Cancer risks among BRCA1 and BRCA2 mutation carriers.
@ast
Cancer risks among BRCA1 and BRCA2 mutation carriers.
@en
P2860
P921
P356
P1476
Cancer risks among BRCA1 and BRCA2 mutation carriers.
@en
P2093
E Friedman
P2860
P2888
P356
10.1038/SJ.BJC.6603535
P407
P577
2007-01-01T00:00:00Z
2007-01-15T00:00:00Z